1 Updates

Paid Rheumatoid Arthritis (RA) Clinical Trial Now Enrolling at Achieve Clinical Research in Birmingham, Alabama; Accepting M/F Patients with RA Age 18 - 75

Oct 16 2013, 4:18pm CDT | by PR.com

Achieve is conducting a study to evaluate the safety and efficacy of a new drug versus rituximab in patients with moderately to severely active rheumatoid arthritis (RA).

Birmingham, AL, October 16, 2013 --(PR.com )-- *To see if you qualify for this RA Clinical Trial in Alabama, visit Achieve Clinical Research on the web (http://www.achieveclinical.com/). There is...

Filed under: news

YouTube Videos

 
 
 

39 weeks ago

Paid Rheumatoid Arthritis (RA) Clinical Trial Now Enrolling at Achieve Clinical Research in Birmingham, Alabama; Accepting M/F Patients with RA Age 18 - 75

Oct 16 2013, 4:18pm CDT | by PR.com

Achieve is conducting a study to evaluate the safety and efficacy of a new drug versus rituximab in patients with moderately to severely active rheumatoid arthritis (RA).

Birmingham, AL, October 16, 2013 --(PR.com )-- *To see if you qualify for this RA Clinical Trial in Alabama, visit Achieve Clinical Research on the web (http://www.achieveclinical.com/). There is no cost to participate, no insurance is required, and you may receive compensation for time and travel.

Study Design

This is a 48-week, double-blind, multiple dose, parallel group trial to compare the safety, efficacy, immunogenicity and tolerability of an experimental drug to Rituxan and MabThera in patients with moderately to severely active RA. Patients will be enrolled across 250 clinical sites, in 26 countries.

Part I (48-week duration) will include 150 patients, which is considered sufficient for pharmacokinetics (PK) testing. Part II consists of a 48-week comparative safety/efficacy analyses with an additional 150 patients.

Background & Rationale

Rheumatoid arthritis (RA) is a chronic systemic inflammatory disease characterized by synovial inflammation in the joints and consequently, progressive joint destruction. Depending on the severity of the disease, systemic manifestations may occur including lung disease, rheumatoid nodules and cardiovascular system effects. Without effective RA treatment, this disease may lead to severe functional disabilities, and therefore a considerable reduction in quality of life for the patient. The prevalence of RA varies with factors such as gender, race and smoking status and is approximately 0.5-1%.

B lymphocytes (B cells) are thought to play a crucial role in the pathogenesis of RA. They are also the primary source of rheumatoid factors (RFs) and anti-cyclic citrullinated peptide (anti-CCP) antibodies which contribute to the formation of immune complexes and complement activation in inflamed joints. Thus, B cell targeted therapy could play an important role in RA through a reduction in the B cell count as well as a reduction in B cell-mediated downstream effects on other cell types involved in the inflammatory response.

Primary Objectives

The primary objectives of this trial are:

To show PK similarity of this new drug to MabThera and Rituxan and of Rituxan to MabThera (three-way PK similarity).
To establish statistical equivalence of efficacy of this new drug and Rituxan/MabThera, in patients with moderately to severely active RA

Inclusion Criteria

Male or female participants, between 18 and 80 years of age, who have a diagnosis of moderately to severely active RA for at least 6 months

Patients must have had an inadequate response or intolerance to conventional DMARD therapy including at least one TNF inhibitor.

Positive for RF and/or anti-CCP antibodies.

Current treatment for RA on an outpatient basis:

-- Must be currently receiving and tolerating oral or parenteral MTX therapy at a dose of 15-25 mg per week (dose may be as low as 10 mg per week if the patient is unable to tolerate a higher dose) for at least 12 weeks immediately prior to Day 1.

-- Patients must be willing to receive oral folic acid (at least 5 mg/week or as per local practice) or equivalent during the entire study (mandatory co-medication for MTX treatment).

-- Biologic agents and DMARDs (other than MTX) must be withdrawn at least 2 weeks prior to Day 1.

-- Leflunomide must be withdrawn at least 8 weeks prior to Day 1 or a minimum of 2 weeks prior to Day 1 if after 11 days of standard cholestyramine washout.

-- If receiving current treatment with oral corticosteroids (other than intra-articular or parenteral), the dose must not exceed 10 mg/day prednisolone or equivalent. During the 4 weeks prior to Baseline (Day 1) the dose must remain stable.

-- Intra-articular and parenteral corticosteroids are not permitted within 6 weeks prior to Baseline Day 1 or throughout the trial, with the exception of IV administration of 100 mg methylprednisolone 30 to 60 minutes prior to each infusion
as this is part of the trial procedures.

-- Any concomitant non-steroidal anti-inflammatory drugs (NSAIDs) must be stable for at least 2 weeks prior to Day 1.

-- Patients may be taking oral hydroxychloroquine provided that the dose is not greater than 400 mg/day or chloroquine provided that the dose is not greater than 250 mg/day.

*Achieve Clinical Research conducts Phase II-IV Clinical Trials in Alabama. For more information about participating in an RA Clinical Study, please visit our website or contact us directly at (205) 380-6434.

Contact Information:
Achieve Clinical Research
Lashondra Cade
(205) 380-6434 320
Contact via Email
www.achieveclinical.com

Read the full story here: http://www.pr.com/press-release/520216

Press Release Distributed by PR.com

Source: PR.com

 

Don't miss ...

 

blog comments powered by Disqus

Latest stories

US approves probes against Chinese tires
Washington, July 23 (IANS) The US International Trade Commission (USITC) Tuesday approved the anti-dumping and countervailing duties investigations against imports of certain passenger vehicle and light truck tires from China.
 
 
Nigeria poverty level drops: Report
Lagos, July 23 (IANS) Poverty rate in Nigeria has dropped from 35.2 percent to 33.1 percent in 2013, a latest World Bank report said Tuesday.
 
 
UN agencies call for actions against polio in Syria
Geneva, July 23 (IANS) The World Health Organisation and the United Nations International Children's Emergency Fund Tuesday said in a report that actions are needed to protect children against polio in Syria as polio cases resurfaced in the conflict-stricken country.
 
 
US airlines cancel flights to Israel
Washington, July 23 (IANS) Two major US civil aviation giants, Delta Airlines and US Airways announced Tuesday that they have cancelled flights to Israel due to safety and security concerns.
 
 
 

Latest from the Network

Kerry, Abbas discuss Gaza ceasefire
Ramallah, July 23 (IANS) US Secretary of State John Kerry Wednesday along with Palestinian President Mahmoud Abbas discussed the possibilities of reaching a ceasefire to end the on-going violence in the Gaza Strip....
Read more on Politics Balla
 
Convertible Owners Have More Bucks And Brains Than Other Drivers, Survey Says
Most Popular Convertibles In The U.S. In what might be a case of twisted logic, data suggests it takes an above-average income and education to drive what, by all measures, is one of the least practical cars on the...
Read more on Auto Balla
 
Wine Tourism Mega Hit: Just Add Music
BAROLO, Italy –Let’s start with some numbers. 750. That’s about the everyday population of the comune of Barolo, the wine mecca of the Piedmont region that produces the red wines widely regarded as Italy’s very best. 20...
Read more on Auto Balla
 
Diesels, Despite Competition,Will Still Lead Fuel Frugality March - Audi
MALMO, Sweden – Diesel engines are under attack on many fronts, but Audi still believes they have a solid future and will even lead the way in saving fuel for a while yet. Ever-tightening clean-air regulations make...
Read more on Auto Balla
 
Tesla Motors Idles California Plant To Prepare For Model X Production
Tesla Motors is halting production at its assembly plant in Fremont, California to prepare for the rollout of its electric crossover vehicles, known as the Model X. Tesla will also enhance its existing assembly line to...
Read more on Auto Balla
 
Taiwan Depends On New Apple Models, Tablet Decline Shows
In November Apple came out with its thin, light tablet the iPad Air, and a new iPad model is due in late 2014, tech media say. That leaves a year with nothing new from the Silicon Valley consumer tech icon. Some might...
Read more on Apple Balla
 
UEFA Champions League qualifying results
London, July 23 (IANS) Following are the results from the UEFA Champions League second qualifying round, second leg, according to Xinhua: FK Sutjeska (Montenegro), 0 FC Sheriff, Moldova, 3 Sheriff qualify 5-0 on...
Read more on Sport Balla
 
Lady Gaga joins water conservation campaign
Los Angeles, July 23 (IANS) Singer Lady Gaga has joined a campaign urging the people of California to conserve water. In a new video for the Save Our Water campaign, the singer reveals she learned all about California...
Read more on Celebrity Balla
 
Jada Pinkett Smith stands up against sexual assault
Los Angeles, July 23 (IANS) Actress Jada Pinkett Smith has taken on cause of sexual assault after a family incident. Smith is speaking up for rape victims, a cause that nearly hit close to home for the actress, who...
Read more on Celebrity Balla